Cerevel Therapeutics Holdings, Inc.
CERE
Clasificación en acciones
#2811
Cerevel Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical firm... Cerevel Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing treatments for a range of neuroscience disorders. The company boasts a robust pipeline of therapeutic candidates currently undergoing various phases of clinical evaluation. Key assets include emraclidine, a positive allosteric modulator (PAM) in Phase 1b trials for schizophrenia. Another PAM, Darigabat, is being assessed in a Phase 2 proof-of-concept study for drug-resistant focal onset seizures in epilepsy, as well as in a Phase 1 trial for acute anxiety. For Parkinson's disease, Cerevel is advancing Tavapadon, a selective dopamine D1/D5 partial agonist, through Phase 3 clinical trials for both early and late stages of the condition. A related compound, CVL-871, also a selective dopamine D1/D5 partial agonist, is in Phase 2a trials for dementia-related apathy. The company's portfolio further includes CVL-936, a selective dopamine D3-preferring antagonist in Phase I for substance use disorder; CVL-354, a selective kappa-opioid receptor antagonist targeting major depressive disorder and substance use disorder; and CVL-047, a selective PDE4 inhibitor also aimed at major depressive disorder and substance use disorder. Beyond individual compounds, Cerevel is actively developing an M4 agonist program for psychosis and related indications, alongside an LRRK2 inhibitor program designed to address the progression of Parkinson's disease. Founded in 2018, Cerevel Therapeutics is headquartered in Cambridge, Massachusetts.
Precio por acción
$44.96
Última sincronización: 2024-08-01
Capitalización bursátil
$6.67B
Cambio (1 día)
0.00%
Cambio (1 año)
0.00%
País
US
Comercio Cerevel Therapeutics Holdings, Inc. (CERE)
Categoría
Healthcare
Ganancias de Cerevel Therapeutics Holdings, Inc. (CERE)
Ganancias en Mar 2024 TTM: $-459.91M
Secondo gli ultimi rapporti finanziari di Cerevel Therapeutics Holdings, Inc., gli utili attuali della società sono $-459.91M. Nel 2022, la società ha registrato un utile di $-351.35M, una disminución en comparación con agli utili del 2021, che erano di $-225.33M. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Cerevel Therapeutics Holdings, Inc. desde 2012 hasta 2026
Ganancias al final de cada año
| Año | Ganancias | Cambiar |
|---|---|---|
| 2026 (TTM) | $-459.91M | 6.38% |
| 2023 | $-432.34M | 23.05% |
| 2022 | $-351.35M | 55.92% |
| 2021 | $-225.33M | 48.08% |
| 2020 | $-152.17M | 18.56% |
| 2019 | $-128.34M | -72.32% |
| 2018 | $-463.64M | 1,546.73% |
| 2015 | $-28.16M | -3.97% |
| 2014 | $-29.32M | -9.81% |
| 2013 | $-32.51M | 10.55% |
| 2012 | $-29.41M | 0.00% |
Ganancias de empresas similares o competidoras
| Empresa | Ganancias | Diferencia de ganancias | País |
|---|---|---|---|
| $5.27B | -1,246.94% |
US
|
|
| $-3.09B | 571.22% |
US
|
|
| $-4.02B | 773.25% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -524.14% |
NL
|
